70 patents
Page 2 of 4
Utility
Methods For Reducing Liver Fat and For Treating Fatty Liver Disorders
24 Nov 22
Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis).
Ada Lee, Andreas Grauer, Joseph Belanoff
Filed: 4 May 22
Utility
Optimizing Mifepristone Absorption
11 Aug 22
The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration.
Joe Belanoff, Robert Roe, Caroline Loewy
Filed: 20 Apr 22
Utility
Methods of Preparing Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulators
21 Jul 22
The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.
Jeffrey Mark DENER, Hazel Joan HUNT, Travis LEMONS, Gary REID, Kilian GARREC, Thomas C. STEPHENS, Adam Daisuke GAMMACK YAMAGATA, Yunguo LU
Filed: 22 Dec 21
Utility
Method of Preparing Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators
14 Jul 22
The present invention provides methods of preparing 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one, and 2-amino-6-((1r,4r)-4-phenylcyclohexyl)-5-(3-(trifluoromethyl)benzyl)pyrimidin-4(3H)-one monohydrate, as well as new intermediate compounds.
Jeffrey Mark Dener, Hazel Joan Hunt, Nicholas David Tyrrell
Filed: 20 Dec 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and Paclitaxel, a Dual Substrate of CYP2C8 and CYP3A4
16 Jun 22
Hazel Hunt, Joseph Custodio
Filed: 15 Feb 22
Utility
Concomitant Administration of Glucocorticoid Receptor Modulators and CYP3A Inhibitors
24 Mar 22
Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors.
Joseph K. Belanoff
Filed: 7 Dec 21
Utility
Methods of Treating Neuroepithelial Tumors Using Selective Glucocorticoid Receptor Modulators
17 Mar 22
Applicant discloses methods for treating a glucocorticoid receptor positive (GR+) neuroepithelial tumor in a subject, comprising administering a selective glucocorticoid receptor modulator (SGRM) in an amount effective to reduce the tumor load in subject.
Andreas G. Moraitis
Filed: 19 Nov 21
Utility
Use of Glucocorticoid Receptor Antagonists In Combination with Glucocorticoids to Treat Adrenal Insufficiency
3 Mar 22
This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof.
Andreas G. MORAITIS, Pejman COHAN, Joseph K. BELANOFF
Filed: 12 Nov 21
Utility
Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors
3 Mar 22
Methods for treating, identifying and localizing tumors expressing somatostatin receptors (SRs), including methods of enhancing the efficacy of imaging techniques by administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) effective to increase SR expression in tumors.
Andreas G. Moraitis
Filed: 19 Dec 19
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and CYP2C9 Substrates
2 Dec 21
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and CYP2C8 Substrates
2 Dec 21
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Concomitant Administration of Glucocorticoid Receptor Modulator Relacorilant and Paclitaxel, a Dual Substrate of CYP2C8 and CYP3A4
2 Dec 21
Hazel Hunt, Joseph Custodio
Filed: 26 May 21
Utility
Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulators
2 Dec 21
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators, including their use for treating amyotrophic lateral sclerosis (ALS).
Hazel Hunt, Tony Johnson, Nicholas Ray, Iain Walters
Filed: 28 Jul 21
Utility
Formulations of Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators
25 Nov 21
The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
Yip-Fong CHIA, Stephen ARBOLEDA, Yan ALSMEYER, Gordon DAVIS, Tyler CLIKEMAN
Filed: 5 May 21
Utility
Polymorphs of Pyrimidine Cyclohexyl Glucocorticoid Receptor Modulators
25 Nov 21
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione, and methods of making and using the same.
Hazel Joan HUNT, Lorraine DONAGHY, Keith LORIMER, Nathan Jay DIXON, Jeffrey Mark DENER
Filed: 5 May 21
Utility
Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator
4 Nov 21
Andreas Moraitis
Filed: 9 Jun 21
Utility
Method for Differentially Diagnosing Acth-dependent Cushing's Syndrome
7 Oct 21
This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome.
Andreas G. Moraitis
Filed: 21 Jun 21
Utility
Pyrimidine Cyclohexenyl Glucocorticoid Receptor Modulators
5 Aug 21
The present invention provides a class of pyrimidinedione cyclohekenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.
Hazel HUNT, Damien Francis Philippe CREPIN, Joseph Thomas HILL-COUSINS, Thomas Matthew BAKER, Lorna DUFFY
Filed: 3 Jun 19
Utility
Use of Glucocorticoid Receptor Modulators to Potentiate Checkpoint Inhibitors
8 Jul 21
This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.
Hazel Hunt
Filed: 23 Mar 21
Utility
Methods for Shrinking Pituitary Tumors
17 Jun 21
Andreas Moraitis
Filed: 25 Feb 21